Stocks News

LAST PRICE
75.6400
TODAY'S CHANGE (%)
Trending Up3.1400 (4.3310%)

Bid / Lots
75.0000/ 2
Ask / Lots
75.6300/ 1
Open / Previous Close
72.3000 / 72.5000
Day Range
Low 72.3000
High 75.9800
52 Week Range
Low 55.0200
High 98.4000
Volume
347,287
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

May 8, 2024
- DJ Axsome Therapeutics Is Maintained at Buy by Mizuho, from 7:23AM ET on Wednesday May 08, 2024 by Dow Jones
  7:23AM ET on Wednesday May 08, 2024 by Dow Jones
  Companies Mentioned: AXSM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AXSM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 08, 2024 07:23 ET (11:23 GMT)
- Axsome Therapeutics to Present at Upcoming Investor Conferences, from 7:00AM ET on Wednesday May 08, 2024 by GlobeNewswire
  7:00AM ET on Wednesday May 08, 2024 by GlobeNewswire
  Companies Mentioned: AXSM
- Axsome Therapeutics to Present at Upcoming Investor Conferences, from 7:00AM ET on Wednesday May 08, 2024 by Dow Jones
  7:00AM ET on Wednesday May 08, 2024 by Dow Jones
  Companies Mentioned: AXSM
  
  Axsome Therapeutics to Present at Upcoming Investor Conferences
  
  NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in two upcoming investor conferences.
- Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating, from 6:13AM ET on Wednesday May 08, 2024 by MT Newswires
  6:13AM ET on Wednesday May 08, 2024 by MT Newswires
  Companies Mentioned: AXSM
  06:13 AM EDT, 05/08/2024 (MT Newswires) -- Axsome Therapeutics (AXSM) has an average rating of buy and price targets ranging from $97 to $190, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research f...
May 7, 2024
- DJ Axsome Therapeutics Is Maintained at Buy by Citigroup, from 1:27PM ET on Tuesday May 07, 2024 by Dow Jones
  1:27PM ET on Tuesday May 07, 2024 by Dow Jones
  Companies Mentioned: AXSM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AXSM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 07, 2024 13:27 ET (17:27 GMT)

Today
- --Mizuho Adjusts Price Target on Insmed to $36 From $35, Keeps Buy Rating, from 9 hours ago by MT Newswires
  9 hours ago by MT Newswires
  Companies Mentioned: INSM
- TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center, from 11 hours ago by Business Wire
  11 hours ago by Business Wire
  Companies Mentioned: MRVI
May 10, 2024
- UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating, from 11:32AM ET on Friday May 10, 2024 by MT Newswires
  11:32AM ET on Friday May 10, 2024 by MT Newswires
  Companies Mentioned: ARWR
- Mizuho Securities Raises Price Target on Insmed to $36 From $35, Keeps Buy Rating, from 10:36AM ET on Friday May 10, 2024 by MT Newswires
  10:36AM ET on Friday May 10, 2024 by MT Newswires
  Companies Mentioned: INSM
May 9, 2024
- Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2, from 4:34PM ET on Thursday May 09, 2024 by MT Newswires
  4:34PM ET on Thursday May 09, 2024 by MT Newswires
  Companies Mentioned: ARWR
- Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule, from 4:05PM ET on Thursday May 09, 2024 by GlobeNewswire
  4:05PM ET on Thursday May 09, 2024 by GlobeNewswire
  Companies Mentioned: MRVI
- UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating, from 10:53AM ET on Thursday May 09, 2024 by MT Newswires
  10:53AM ET on Thursday May 09, 2024 by MT Newswires
  Companies Mentioned: MRVI
- Baird Adjusts Price Target on Maravai LifeSciences to $10 From $8, Keeps Outperform Rating, from 10:11AM ET on Thursday May 09, 2024 by MT Newswires
  10:11AM ET on Thursday May 09, 2024 by MT Newswires
  Companies Mentioned: MRVI
- Insmed's Q1 Net Loss Narrows as Revenue Advances, from 7:45AM ET on Thursday May 09, 2024 by MT Newswires
  7:45AM ET on Thursday May 09, 2024 by MT Newswires
  Companies Mentioned: INSM
- Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Thursday May 09, 2024 by PR Newswire
  7:00AM ET on Thursday May 09, 2024 by PR Newswire
  Companies Mentioned: INSM

Axsome Therapeutics Inc
NASDAQ:AXSMUnited States

Search Criteria

May 8, 2024

DJ Axsome Therapeutics Is Maintained at Buy by Mizuho, from 7:23AM ET on Wednesday May 08, 2024 by Dow Jones

Axsome Therapeutics to Present at Upcoming Investor Conferences, from 7:00AM ET on Wednesday May 08, 2024 by GlobeNewswire

Axsome Therapeutics to Present at Upcoming Investor Conferences, from 7:00AM ET on Wednesday May 08, 2024 by Dow Jones

Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating, from 6:13AM ET on Wednesday May 08, 2024 by MT Newswires

May 7, 2024

DJ Axsome Therapeutics Is Maintained at Buy by Citigroup, from 1:27PM ET on Tuesday May 07, 2024 by Dow Jones

Peers Headlines

Today

--Mizuho Adjusts Price Target on Insmed to $36 From $35, Keeps Buy Rating, from 9 hours ago by MT Newswires

TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center, from 11 hours ago by Business Wire

May 10, 2024

UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating, from 11:32AM ET on Friday May 10, 2024 by MT Newswires

Mizuho Securities Raises Price Target on Insmed to $36 From $35, Keeps Buy Rating, from 10:36AM ET on Friday May 10, 2024 by MT Newswires

May 9, 2024

Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2, from 4:34PM ET on Thursday May 09, 2024 by MT Newswires

Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule, from 4:05PM ET on Thursday May 09, 2024 by GlobeNewswire

UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating, from 10:53AM ET on Thursday May 09, 2024 by MT Newswires

Baird Adjusts Price Target on Maravai LifeSciences to $10 From $8, Keeps Outperform Rating, from 10:11AM ET on Thursday May 09, 2024 by MT Newswires

Insmed's Q1 Net Loss Narrows as Revenue Advances, from 7:45AM ET on Thursday May 09, 2024 by MT Newswires

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Thursday May 09, 2024 by PR Newswire